{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T20:55:35Z","timestamp":1771102535585,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.arcmed.2021.06.003","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T03:49:24Z","timestamp":1626407364000},"page":"51-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Alterations in Sialylation Patterns are Significantly Associated with Imatinib Mesylate Resistance in Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"53","author":[{"given":"Kinjal D.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maitri","family":"De","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Disha D.","family":"Jethva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharati S.","family":"Rathod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhudas S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2021.06.003_bib0001","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and Resistance to BCR-ABL1-Targeted Therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0002","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3389\/fonc.2019.00939","article-title":"BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia","volume":"9","author":"Loscocco","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0003","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"O'Hare","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0004","doi-asserted-by":"crossref","first-page":"108","DOI":"10.6026\/97320630010108","article-title":"Differences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia","volume":"10","author":"Hai","year":"2014","journal-title":"Bioinformation"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0005","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1182\/blood.V78.5.1155.1155","article-title":"Does the breakpoint within the major breakpoint cluster region (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature","volume":"78","author":"Mills","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0006","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1365-2141.1995.tb08362.x","article-title":"Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival","volume":"89","author":"Shepherd","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0007","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41375-019-0562-1","article-title":"Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type","volume":"33","author":"Baccarani","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0008","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1002\/cncr.31408","article-title":"The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia","volume":"124","author":"Ercaliskan","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0009","first-page":"803","article-title":"Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia","volume":"4","author":"de Lemos","year":"2005","journal-title":"Genet Mol Res"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0010","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.clml.2017.06.009","article-title":"Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib","volume":"17","author":"Pagnano","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0011","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00277-009-0822-7","article-title":"Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts","volume":"89","author":"Sharma","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0012","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/labinvest.2016.50","article-title":"Alpha-2, 3-sialyltransferases regulate the multidrug resistance of chronic myeloid leukemia through miR-4701-5p targeting ST3GAL1","volume":"96","author":"Li","year":"2016","journal-title":"Lab Invest"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0013","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13046-019-1208-x","article-title":"The regulatory ZFAS1\/miR-150\/ST6GAL1 crosstalk modulates sialylation of EGFR via PI3K\/Akt pathway in T-cell acute lymphoblastic leukemia","volume":"38","author":"Liu","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0014","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13058-015-0652-6","article-title":"The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features","volume":"17","author":"Aloia","year":"2015","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0015","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1073\/pnas.1302825110","article-title":"Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells","volume":"110","author":"Liang","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0016","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4137\/CIN.S39839","article-title":"Characterization of Gene Expression Patterns among Artificially Developed Cancer Stem Cells Using Spherical Self-Organizing Map","volume":"15","author":"Seno","year":"2016","journal-title":"Cancer Inform"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0017","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41419-018-1101-0","article-title":"Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-\u03b21-induced EMT and confers paclitaxel resistance in ovarian cancer","volume":"9","author":"Wu","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0018","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0019","series-title":"Varly's Practical Clinical Biochemistry","first-page":"407","article-title":"Determination of plasma protein","author":"Gowenlock","year":"2006"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0020","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1042\/bj1590457","article-title":"Stable thiobarbituric acid chromophore with dimethyl sulphoxide. Application to sialic acid assay in analytical de-O-acetylation","volume":"159","author":"Skoza","year":"1976","journal-title":"Biochem J"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0021","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/jop.12976","article-title":"Aberrant sialylation plays a significant role in oral squamous cell carcinoma progression","volume":"49","author":"Mehta","year":"2020","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0022","first-page":"1479","article-title":"Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir","volume":"19","author":"Azad","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0023","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4103\/0019-509X.176741","article-title":"Simple multiplex RT-PCR for identifying common fusion BCR-ABL transcript types and evaluation of molecular response of the a2b2 and a2b3 transcripts to Imatinib resistance in north Indian chronic myeloid leukemia patients","volume":"52","author":"Mir","year":"2015","journal-title":"Indian J Cancer"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0024","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4103\/IJPM.IJPM_726_17","article-title":"Distribution of common BCR-ABL fusion transcripts and their impact on treatment response in Imatinib treated CML patients: A study from India","volume":"62","author":"Sazawal","year":"2019","journal-title":"Indian J Pathol Microbiol"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12291-018-0779-1","article-title":"A Prognostic and Predictive Study of BCR-ABL Expression Based on Characterization of Fusion Transcripts","volume":"35","author":"Upadhyay","year":"2020","journal-title":"Indian J Clin Biochem"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0026","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/10428199209067600","article-title":"Molecular diagnosis and follow up in myeloproliferative syndromes and acute leukemias: correlation between expression of fusion transcripts and disease progression in chronic myeloid leukemia","volume":"21","author":"L\u00e9glise","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0027","doi-asserted-by":"crossref","first-page":"e809","DOI":"10.1002\/mgg3.809","article-title":"Association of BCR\/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients","volume":"7","author":"Khazaal","year":"2019","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0028","first-page":"747","article-title":"Clinical application of serum levels of sialic acid, fucose and seromucoid fraction as tumour markers in human leukemias","volume":"14","author":"Patel","year":"1994","journal-title":"Anticancer Res"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0029","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10719-016-9755-2","article-title":"Glycosylation: a hallmark of cancer?","volume":"34","author":"Vajaria","year":"2017","journal-title":"Glycoconj J"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0030","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/iub.1351","article-title":"\u03b1-2,8-Sialyltransferase Is Involved in the Development of Multidrug Resistance via PI3K\/Akt Pathway in Human Chronic Myeloid Leukemia","volume":"67","author":"Zhang","year":"2015","journal-title":"IUBMB Life"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0031","doi-asserted-by":"crossref","first-page":"60074","DOI":"10.18632\/oncotarget.11054","article-title":"Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0032","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.gene.2017.05.030","article-title":"Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expression","volume":"626","author":"Zhou","year":"2017","journal-title":"Gene"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0033","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJM200310093491521","article-title":"Residual disease in chronic myeloid leukemia after induction of molecular remission","volume":"349","author":"Lange","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0034","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1158\/0008-5472.CAN-17-3376","article-title":"Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity","volume":"78","author":"B\u00fcll","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0035","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1021\/nn5061964","article-title":"Targeted delivery of a sialic acid-blocking glycomimetic to cancer cells inhibits metastatic spread","volume":"9","author":"B\u00fcll","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.arcmed.2021.06.003_bib0036","doi-asserted-by":"crossref","first-page":"e31234","DOI":"10.1371\/journal.pone.0031234","article-title":"Androgen-regulated transcriptional control of sialyltransferases in prostate cancer cells","volume":"7","author":"Hatano","year":"2012","journal-title":"PLoS One"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440921001259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440921001259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:51:16Z","timestamp":1759261876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440921001259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0188440921001259"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2021.06.003","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alterations in Sialylation Patterns are Significantly Associated with Imatinib Mesylate Resistance in Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2021.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}